Johnson & Johnson is a prime example of the kind of stock doing well in the broader market as investors shy away from the volatile artificial intelligence trade. "[J & J] is a metaphor for what's working," Jim Cramer said Monday on CNBC, as shares of the pharma and medtech giant hit another all-time high before reversing lower in a terrible market. Investors have been rotating into defensive sectors, such as healthcare and consumer staples, as stocks tied to the AI boom have fallen on hard times. It's an evolving dynamic Jim has been capitalizing on in recent weeks as the Club has been trimming data center exposure and diversifying into defensives. It was a big part of our Annual Meeting earlier this month. Over the past month, healthcare and consumer staples are the market's two top performers, with gains of 7% and 6%, respectively, crushing the S & P 500 's nearly 3% decline. Tech, over the same stretch, is down more than 9%, due to concerns about what the Democratic wave in the midterm elections might mean for…
Jim Cramer says J&J is a 'metaphor for what's working' in the stock market
In short
The healthcare sector has climbed 7% over the past month, contrasting sharply with a more than 9% drop in tech stocks. Johnson & Johnson has capitalized on this trend, gaining 20% since early April and recently reaching an all-time high before pulling back. To fuel future growth, the company agreed to acquire Ollin Biosciences for up to $3.33 billion to expand its treatments for serious eye diseases. Meanwhile, management plans to address weaknesses in its MedTech division by spinning off its orthopedics business by 2027.
Key points
- Market leadership is rotating toward defensive assets as investors pull back from high-vo…: Market leadership is rotating toward defensive assets as investors pull back from high-volatility artificial intelligence stocks.
- Strategic acquisitions in specialized biopharmaceuticals are helping major healthcare fir…: Strategic acquisitions in specialized biopharmaceuticals are helping major healthcare firms reinforce their long-term drug pipelines.
- Planned corporate restructuring includes spinning off an underperforming orthopedics busi…: Planned corporate restructuring includes spinning off an underperforming orthopedics business unit by 2027 to improve overall margins.